Neurocrine Biosciences (NBIX) Misses Q4 EPS by 11c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $138.40 -0.39%
EPS Growth %: -12.4%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
OCCI, IPX, ALZN, More
EPS Growth %: -12.4%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.07, $0.11 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $94.52 million versus the consensus estimate of $87.77 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- Moody’s upgrades Brinker to Ba1 on Chili’s growth and debt reduction
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
